Elicio Therapeutics Inc. (ELTX) — Cash Flow-to-Debt Ratio
Elicio Therapeutics Inc. (ELTX) has a Cash Flow-to-Debt Ratio of -0.35x as of June 2026, meaning its operating cash flow of $-8.16 Million could theoretically repay 0% of its total liabilities ($23.39 Million) in one year. See Elicio Therapeutics Inc. (ELTX) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Elicio Therapeutics Inc. Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Elicio Therapeutics Inc. across 10 annual periods. For the full cash flow conversion analysis, see ELTX operating cash flow.
Annual Cash Flow-to-Debt Ratio for Elicio Therapeutics Inc. (2012–2025)
Year-by-year debt coverage analysis for Elicio Therapeutics Inc.. Check ELTX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.53x | $-36.95 Million | $24.23 Million | ▼ -62.5% |
| 2024 | -0.94x | $-37.07 Million | $39.49 Million | ▲ +54.7% |
| 2023 | -2.07x | $-32.69 Million | $15.77 Million | ▼ -28.5% |
| 2022 | -1.61x | $-22.18 Million | $13.75 Million | ▼ -1.1% |
| 2021 | -1.60x | $-23.94 Million | $15.01 Million | ▼ -860.4% |
| 2020 | -0.17x | $-22.89 Million | $137.80 Million | ▲ +79.4% |
| 2019 | -0.81x | $-24.59 Million | $30.47 Million | ▲ +22.4% |
| 2018 | -1.04x | $-8.02 Million | $7.72 Million | ▼ -462.7% |
| 2013 | 0.29x | $1.89 Million | $6.60 Million | ▲ +82.7% |
| 2012 | 0.16x | $1.07 Million | $6.79 Million | — |